Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Halpern

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Archives of Endocrinology and Metabolism|April 7, 2021
Irisin and its relationship with metabolic health: more questions than answersBruno Halpern
The American Journal of Clinical Nutrition|December 3, 2019
Response to "Metabolic adaptation is not observed after 8 weeks of overfeeding but energy expenditure variability is associated with weight recovery"Bruno Halpern
Archives of Endocrinology and Metabolism|May 19, 2016
Elevated irisin and alanine aminotransferase levels in hypothyroidism: role of oxidative stress?Bruno Halpern
Expert Opinion on Drug Safety|December 23, 2014
Why are anti-obesity drugs stigmatized?Bruno Halpern, Alfredo Halpern
Expert Opinion on Drug Safety|January 8, 2015
Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medicationsBruno Halpern, Alfredo Halpern
Reviews in Endocrine & Metabolic Disorders|July 17, 2025
Looking beyond fat in obesity: the frequently overlooked importance of muscle massRefaat Hegazi, Bruno Halpern
Diabetology & Metabolic Syndrome|January 3, 2024
Pharmacotherapy for obesity: moving towards efficacy improvementWalmir Coutinho, Bruno Halpern
Women & Health|May 23, 2022
Obesity, weight loss and gynecologic neoplasms: a narrative reviewBruno Halpern, Thiago Bosco Mendes
Expert Opinion on Drug Safety|October 13, 2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended releaseBruno Halpern, Marcio C Mancini
Archives of Endocrinology and Metabolism|January 14, 2021
Intermittent fasting for obesity and related disorders: unveiling myths, facts, and presumptionsBruno Halpern, Thiago Bosco Mendes
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Archives of Endocrinology and Metabolism|April 7, 2021
Irisin and its relationship with metabolic health: more questions than answersBruno Halpern
The American Journal of Clinical Nutrition|December 3, 2019
Response to "Metabolic adaptation is not observed after 8 weeks of overfeeding but energy expenditure variability is associated with weight recovery"Bruno Halpern
Archives of Endocrinology and Metabolism|May 19, 2016
Elevated irisin and alanine aminotransferase levels in hypothyroidism: role of oxidative stress?Bruno Halpern
Expert Opinion on Drug Safety|December 23, 2014
Why are anti-obesity drugs stigmatized?Bruno Halpern, Alfredo Halpern
Expert Opinion on Drug Safety|January 8, 2015
Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medicationsBruno Halpern, Alfredo Halpern
Reviews in Endocrine & Metabolic Disorders|July 17, 2025
Looking beyond fat in obesity: the frequently overlooked importance of muscle massRefaat Hegazi, Bruno Halpern
Diabetology & Metabolic Syndrome|January 3, 2024
Pharmacotherapy for obesity: moving towards efficacy improvementWalmir Coutinho, Bruno Halpern
Women & Health|May 23, 2022
Obesity, weight loss and gynecologic neoplasms: a narrative reviewBruno Halpern, Thiago Bosco Mendes
Expert Opinion on Drug Safety|October 13, 2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended releaseBruno Halpern, Marcio C Mancini
Archives of Endocrinology and Metabolism|January 14, 2021
Intermittent fasting for obesity and related disorders: unveiling myths, facts, and presumptionsBruno Halpern, Thiago Bosco Mendes
Pageof 7